Clinical Trial Update: Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations [Phase 1, Phase 2]

View source ↗

Summary

Pilot trial of BMN 673 (olaparib) in advanced solid tumors with deleterious BRCA mutations completed phases 1 and 2; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Solid Tumors

Drugs mentioned

• BMN 673 (talazoparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Ovarian Cancer, Primary Peritoneal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-01-27